Research by Kostyrko's team at the University of California, USA, has discovered that knocking out UHRF1 can inhibit the growth of KRAS-driven mouse lung cancer tumors, suggesting that UHRF1 may become a potential therapeutic intervention target for KRAS-driven cancers.26 Here, KRAS is linked to lung carcinoma.